Aspira Women's Health Files 8-K

Ticker: AWHL · Form: 8-K · Filed: Jan 13, 2025 · CIK: 926617

Sentiment: neutral

Topics: disclosure, financials, corporate-history

TL;DR

Aspira Women's Health filed an 8-K on Jan 13, 2025, covering Reg FD and financials.

AI Summary

On January 13, 2025, Aspira Women's Health Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Vermillion, Inc., Ciphergen Biosystems Inc., and Abiotic Systems, is incorporated in Delaware and headquartered in Austin, Texas.

Why It Matters

This 8-K filing indicates routine corporate disclosures, including financial statements and potential regulatory information, which are important for investors to monitor the company's status.

Risk Assessment

Risk Level: low — This filing appears to be a standard disclosure and does not immediately indicate significant new risks.

Key Players & Entities

FAQ

What specific financial statements are included in this 8-K filing?

The filing indicates 'Financial Statements and Exhibits' are included, but the specific details of these statements are not provided in the excerpt.

What is the primary purpose of this 8-K filing?

The primary purposes listed are 'Regulation FD Disclosure' and 'Financial Statements and Exhibits'.

When was the earliest event reported in this filing?

The earliest event reported was on January 13, 2025.

What were some of Aspira Women's Health Inc.'s former company names?

The company was formerly known as Vermillion, Inc., Ciphergen Biosystems Inc., and Abiotic Systems.

Where is Aspira Women's Health Inc. headquartered?

The company's business address is located at 12117 Bee Caves Road, Building Three, Suite 100, Austin, TX 78738.

Filing Stats: 432 words · 2 min read · ~1 pages · Grade level 10.9 · Accepted 2025-01-13 07:00:24

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aspira Women's Health Inc. Date: January 13, 2025 By: /s/ Sandra Milligan Sandra Milligan, Interim Chief Executive Officer -3-

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing